Description
An HCV NS3/4A protease inhibitor; inhibits NS3/4A from HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (IC50s = 4.6, 8.9, 3.5, 3.8, 7.9, 6.1, 8.1, and 11.3 nM) in cell-free assays but does not inhibit human chymase, chymotrypsin type II, chymotrypsin type VII, elastase, kallikrein, urokinase, or cathepsin B proteases (IC50s = >200,000 nM); inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 0.85, 0.94, 2.2, 4.6, 1.9, 2.8, 1.4, and 0.86 nM, respectively); inhibits replication of clinical isolates of genotypes 1a (EC50s = 0.05-0.12 nM), 1b (EC50s = 0.20- 0.68 nM), 2a (EC50s = 0.66- 1.9 nM), 2b (EC50s = 1.4- 3.2 nM), 3a (EC50s = 0.71- 3.8 nM), and 4a (EC50s = 0.31- 0.55 nM)
Formal name: (1R,2R)-N-[[[(1R,2R)-2-[[4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl]oxy]cyclopentyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]-cyclopropanecarboxamide, cyclic (1→2)-ether
Synonyms: A-1282576|ABT-493
Molecular weight: 838.9
CAS: 1365970-03-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|Protease Inhibitors||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Hepatitis
